[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07455058":3,"trial-entities:NCT07455058":103,"trial-summary:NCT07455058":107},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":17,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":33,"secondary_outcomes":42,"sex":43,"minimum_age":17,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":44,"std_ages":52,"locations":56,"central_contacts":91,"overall_officials":100,"references":101,"see_also_links":102},"NCT07455058","5600-001","Water Vapor Ablation for Prostate Cancer: Long-Term Registry","Vanquish® Water Vapor Ablation for PrOstate CanceR: Long-Term Registry","RECRUITING","2041-07-31","2026-02","2026-06-12","2026-06-05","Francis Medical Inc.","INDUSTRY",false,"The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).",null,[19],"Prostate Cancer",[],"OBSERVATIONAL",[],{"count":24,"type":25},2500,"ESTIMATED",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31},"DEVICE","Vanquish Therapy","The Francis Medical, Inc. Vanquish Water Vapor Ablation Device (\"Vanquish\" or \"Vanquish System\") is a transurethral thermal water vapor ablation device. The Vanquish System is designed ablate prostate tissue, while minimizing side effects.",[32],"Vanquish Procedure Patients",[34,38],{"measure":35,"description":36,"timeFrame":37},"Primary Efficacy Outcome","Freedom from disease specific mortality.","Through study completion, or up to 15 years.",{"measure":39,"description":40,"timeFrame":41},"Primary Safety Outcome","Rate of complications classified as Clavien-Dindo grades III-V and attributable to the Vanquish procedure and\u002For device over time.\n\n* Grade III: Complications requiring surgical intervention (IIIa: laparoscopic, IIIb: open).\n* Grade IV: Life-threatening complications (IVa: single organ failure, IVb: multi-organ failure).\n* Grade V: Death of a patient.","Through study completion, or up to 15 years",[],"MALE",{"inclusion":45,"exclusion":48,"raw_text":51},[46,47],"Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.","Participant is willing and able to provide written informed consent.",[49,50],"Contraindications per the Vanquish IFU","Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.","Inclusion Criteria:\n\n* Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.\n* Participant is willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindications per the Vanquish IFU\n* Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.",[53,54,55],"CHILD","ADULT","OLDER_ADULT",[57,77],{"facility":58,"status":8,"city":59,"state":60,"zip":61,"country":62,"contacts":63,"geoPoint":74},"The Urology Place, Inc.","San Antonio","Texas","78240","United States",[64,69,71],{"name":65,"role":66,"phone":67,"email":68},"Naveen Kella, MD","CONTACT","210-617-3670","nkella@theupi.com",{"name":65,"role":70},"PRINCIPAL_INVESTIGATOR",{"name":72,"role":73},"Savannah Eggerss, PA","SUB_INVESTIGATOR",{"lat":75,"lon":76},29.42412,-98.49363,{"facility":78,"status":8,"city":79,"state":80,"zip":81,"country":62,"contacts":82,"geoPoint":88},"Urology of Virginia","Virginia Beach","Virginia","23462",[83,87],{"name":84,"role":66,"phone":85,"email":86},"Robert Given, MD","757-452-3461","rgiven@urologyofva.net",{"name":84,"role":70},{"lat":89,"lon":90},36.85293,-75.97799,[92,96],{"name":93,"role":66,"phone":94,"email":95},"Sydney Cartie","6122866855","scartie@francismedical.com",{"name":97,"role":66,"phone":98,"email":99},"Garrett Grenier","763-453-9404","ggrenier@francismedical.com",[],[],[],{"nct_id":4,"conditions":104,"biomarkers":106},[105],"Prostate Carcinoma",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]